## **GOG 250 NCTN DATA ARCHIVE**

October 7, 2019

Data as of: December 19, 2013

## # Notes

- 1 Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study.
- 2 doi: 10.1200/JCO.2014.58.3781
- 3 PMID: 25713428
- 4 Clinical trial information: NCT01012297.
- 5 Data submission information: NCT01012297-D1
- 6 Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Var 1	Type	Label
patid_blind	Character	Patient ID

36 character string

Var 2	Type	Label
nrxn	Numeric	Randomized Treatment Assignment
		Value Label

Value	Label
1	GD+Plac
2	GD+Bev

Var 3	Type	Label
racen	Numeric	Race (Levels combined for patient privacy)

Value	Label
1	White
2	African American
3	Asian/American Indian/unspecified

Var 4	Type	Label			
age	Numeric	Age Rounded to the Year.			
		Continuous Variable			
Var 5	Туре	Label			
perfxn	Numeric	Performance Status (Levels combined for patient privacy)			
		Value Label			
		0 0:Asymptomatic			
		1 1 or 2: Fully Ambulatory or in bed <50%			
Var 6	Type	Label			
prhmynn	Numeric	Prior Hormone Therapy			
		Value Label			
		1 Yes			
		2 No			
Var 7	Туре	Label			
prradynn Numeri		Prior Pelvic Radiation Therapy			
		Value Label			
		1 Yes			
		2 No			

Var 8	Type	Label		
Qcourses	Numeric	Number of treatment courses recieved. Patients indicating no treatment were included in the intent to treat analysis.		
			Continuo	us Variable
Var 9	Туре	Label		
AEExcluded	Numeric	1:Patients exclud	ed from A	E reporting
			Value	Label
			0	Include
			1	Exclude
Var 10	Туре	Label		
Neutropenia	Numeric	Max Grade: Neu	Max Grade: Neutropenia	
		Value	Label	
		Value		1 from AE Analyses
				1 from AE Analyses
			Excluded	1 from AE Analyses
		. 0	Excluded 0	l from AE Analyses
		0 1	Excluded 0	l from AE Analyses

Var 11

Type Label

Thrombocyt

Numeric Max Grade: Thrombocytopenia

Value	Label

Excluded from AE Analyses

0

1 1

2 2

3 3

4 4

Var 12

Type Label

Anemia

Numeric Max Grade: Anemia

Label

Excluded from AE Analyses

0 0

1 1

2 2

3 3

Var 13

Type Label

Hypertens

Numeric Max Grade: Hypertension

Excluded from AE Analyses

0 0

1 1

2 2

3 3 Var 14 Type Label

Thromboemb Numeric Max Grade: Thromboembolic

	Value	Label
value Label		
value Labei		
value Labei		
value Labei		
value Laber		
, arac Eaber		

. Excluded from AE Analyses

0 0

1 1

2 2

3 3

4 4

Var 15 Type Label

Lymphedema Numeric Max Grade: Lymphadema

Value Label

. Excluded from AE Analyses

0

1 1

2 2

Var 16 Type Label

GI Hemorr Numeric

Max Grade: GI Hemorrhage (Due to data cleaning, the AE data may contain slight discrepancies from that reported in Table 2 of the publication.)

Value Label

. Excluded from AE Analyses

0 0

1 1

2 2

3 3

Var 17	Type	Label

Fistula Numeric Max Grade: Fistula

Value	Label
	Excluded from AE Analyses
0	0
3	3

## Var 18 Type Label

GI\_Any Numeric Max Grade: Any GI

Value	Label
	Excluded from AE Analyses
0	0
1	1
2	2
3	3
4	4

Var 19	Type	Label	
respxn	Numeric	Best Response	

Value	Label
1	Complete response
2	Partial response
3	Stable disease
4	Increase disease
6	Not evaluable

Var 20	Type	Label
objresp	Numeric	Objective Response (CR+PR)
		Value Label
		0 CR/PR
		1 Non Resp
Var 21	Туре	Label
MH_stable	Numeric	24 patients who elected to stop study treatment for reasons other than toxicity or disease progression.
		Value Label
		0 Other
		1 Elected to Stop Tx Early
Var 22	Туре	Label
MH_time	Numeric	Months from Withdrawal to Recurrence/Death among 24 patients who elected to stop study treatment for reasons other than toxicity or disease progression.
		Continuous Variable
Var 23	Туре	Label
MH_stat	Numeric	Event status among 24 patients who elected to stop study treatment for reason other than toxicity or disease progression.

Value	Label
•	Excluded from this analysis patient set
1	Censored
2	Event

Var 24	Type	Label	
pfstat	Numeric	Progression Free Surviva	al Status
		Valu	e Label
		1	Censored
		2	Event

Var 25	Type	Label
pfstime	Numeric	Time (months) to documentation of disease progression, death or the last CT Scan

## **Continuous Variable**

Var 26	Type	Label
pfstimeint	Numeric	PFS Time Interval (Weeks- per protocol)

Value	Label
0.1	0.1
8	8
16	16
20	20
24	24
30	30
36	36
44	44
52	52
65	65
78	78
91	91
104	104

Var 27	Type	Label		
respdur	Numeric	Response Duration. Months from response to recurrence or last followup. For Stable Disease, start date is the 1st CT scan. For Increasing Dis or 1st CT Scan not evaluable, RESPDUR=0.		
		Continuous Variable		
Var 28	Туре	Label		
survstat	Numeric	Overall Survival Status (Due to data cleaning, the OS data may contain slig discrepancies from that reported in the publication.)		
		Value Label		
		1 Censored		
		2 Event		
Var 29	Туре	Label		
survtime	Numeric	Time (months) to death or last followup (Due to data cleaning, the OS data may contain slight discrepancies from that reported in the publication.)		

Continuous Variable